Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease

被引:82
|
作者
Adi, Handoko [1 ]
Young, Paul M. [1 ]
Chan, Hak-Kim [1 ]
Agus, Helen [2 ]
Traini, Daniela [1 ]
机构
[1] Univ Sydney, Adv Drug Delivery Grp, Fac Pharm A15, Sydney, NSW 2006, Australia
[2] Univ Sydney, Fac Sci G08, Sydney, NSW 2006, Australia
关键词
Mannitol; Ciprofloxacin; Dry powder inhaler (DPI); Cystic fibrosis; Antibiotics; Mucolytics; RECOMBINANT HUMAN DNASE; HIGH-DOSE IBUPROFEN; PSEUDOMONAS-AERUGINOSA; N-ACETYLCYSTEINE; LUNG-FUNCTION; MUCUS CLEARANCE; INHALATION; ANTIBIOTICS; SAFETY; INFECTION;
D O I
10.1016/j.ejps.2010.03.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to assess the potential of delivering a combination therapy, containing mannitol (a sugar alcohol with osmotic characteristics), and ciprofloxacin hydrochloride (an antibacterial fluoroquinolone), as a dry powder inhaler (DPI) formulation for inhalation. Single and combination powders were produced by spray drying ciprofloxacin and mannitol, from aqueous solution, at different ratios and under controlled conditions, as to obtain similar particle size distributions. Each formulation was characterised using laser diffraction, scanning electron microscopy, differential scanning calorimetry, dynamic vapour sorption, X-ray powder diffraction, and colloidal force microscopy. The in vitro aerosol performance of each formulation was studied using an Aerolizer (R) DPI device and a multi-stage liquid impinger (analysed using high performance liquid chromatography). In addition, a disk diffusion test was performed to assess the in vitro antimicrobial activity of each formulation and starting materials. All formulations had similar particle size distributions, however, the morphology, thermal properties and moisture sorption was dependent on the relative percentages of each component. In general, the combination formulation containing 50% (w/w) mannitol appeared to have the best aerosol performance, good stability and lowest particle cohesion (as measured by colloid probe microscopy). Furthermore, of the formulations tested, mannitol did not appear to alter the effectiveness of the ciprofloxacin antimicrobial activity to Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus pyogenes. The combination of co-spray-dried mannitol and ciprofloxacin from a DPI is an attractive approach to promote mucous clearance in the respiratory tract while simultaneously treating local chronic infection, such as chronic obstructive pulmonary disease and cystic fibrosis. Crown Copyright (C) 2010 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:239 / 247
页数:9
相关论文
共 46 条
  • [1] Development and Characterization of Spray-Dried Combined Levofloxacin-Ambroxol Dry Powder Inhaler Formulation
    Suraweera, Ruwani K.
    Spann, Kirsten M.
    Izake, Emad L.
    Wells, Timothy J.
    Wang, Xiaodong
    Islam, Nazrul
    PHARMACEUTICS, 2024, 16 (12)
  • [2] Towards a More Desirable Dry Powder Inhaler Formulation: Large Spray-Dried Mannitol Microspheres Outperform Small Microspheres
    Kaialy, Waseem
    Hussain, Tariq
    Alhalaweh, Amjad
    Nokhodchi, Ali
    PHARMACEUTICAL RESEARCH, 2014, 31 (01) : 60 - 76
  • [3] Freeze-Dried Mannitol for Superior Pulmonary Drug Delivery via Dry Powder Inhaler
    Kaialy, Waseem
    Nokhodchi, Ali
    PHARMACEUTICAL RESEARCH, 2013, 30 (02) : 458 - 477
  • [4] Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate
    Moenckedieck, M.
    Kamplade, J.
    Fakner, P.
    Urbanetz, N. A.
    Walzel, P.
    Steckel, H.
    Scherliess, R.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 524 (1-2) : 351 - 363
  • [5] New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients
    Pilcer, Gabrielle
    Rosiere, Remi
    Traina, Karl
    Sebti, Thami
    Vanderbist, Francis
    Amighi, Karim
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (06) : 1836 - 1846
  • [6] Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler
    Prime, David
    de Backer, Wilfried
    Hamilton, Melanie
    Cahn, Anthony
    Preece, Andrew
    Kelleher, Dennis
    Baines, Amanda
    Moore, Alison
    Brealey, Noushin
    Moynihan, Jackie
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2015, 28 (06) : 486 - 497
  • [7] In Vitro and In Vivo Performance of Novel Spray Dried Andrographolide Loaded Scleroglucan Based Formulation for Dry Powder Inhaler
    Mali, Ashwin Jagannath
    Bothiraja, Chellampillai
    Purohit, Ravindra Nandlal
    Pawar, Atmaram Pandurang
    CURRENT DRUG DELIVERY, 2017, 14 (07) : 968 - 980
  • [8] Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis
    Yang, Yan
    Tsifansky, Michael D.
    Wu, Chia-Jung
    Yang, Hae In
    Schmidt, Gudrun
    Yeo, Yoon
    PHARMACEUTICAL RESEARCH, 2010, 27 (01) : 151 - 160
  • [9] Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease
    Valderrey, Andrea D.
    Jose Pozuelo, Maria
    Jimenez, Pedro A.
    Macia, Maria D.
    Oliver, Antonio
    Rotger, Rafael
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2010, 68 (01) : 20 - 27
  • [10] Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles
    Marasini, Nirmal
    Sheikh, Zara
    Wong, Chun Y. J.
    Hosseini, Maryam
    Spicer, Patrick T.
    Young, Paul
    Ong, Hui Xin
    Traini, Daniela
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2022, 624